Screening for Type 2 Diabetes > Effectiveness/Harms of Screening Tests Author: Lorraine Lipscombe, MD, FRCPC; Denice S. Feig, MD, MSc, FRCPC
Editorial changes - 2009-05-01
Author information and module status
Key Points
Population at Risk
Effectiveness/Harms of Screening Tests
Effectiveness/Harms of Early Treatment
Direct Evidence that Screening Reduces Adverse Outcomes
Timeline
Cost-Effectiveness
Patient Education
Referral/Consultation
Guidelines

Tables
References
Glossary
What's New
Patient Information
Additional Resources
Tools
Recommendation
Know that risk assessment questionnaires developed to screen for diabetes have inadequate sensitivity and specificity in identifying persons with undiagnosed diabetes.B

Evidence:

  • The questionnaire, “Take the Test, Know the Score,” developed by the ADA, which provides a score based on a family history of diabetes, a history of a macrosomic infant, BMI, age, and physical inactivity, was associated with a sensitivity of 78% and a specificity of 50% for the detection of undiagnosed diabetes in 1471 U.S. adults (66).
  • The Finnish Diabetes Risk Score, which incorporates data on BMI, age, hypertension, diet, and physical activity, found that a score >=9 had a sensitivity of 76% to 77% and a specificity of 66% to 68% for identifying persons with previously undiagnosed diabetes in two cohorts of 4435 Finnish subjects aged 35 to 64 years (69).
  • A questionnaire incorporating age, obesity, physical inactivity, family history of diabetes, hypertension, and BMI was tested in a cohort of 2364 Dutch subjects aged 50 to 74 years, and it was found to be 72% to 78% sensitive and 55% specific for detecting undiagnosed diabetes (70).

Comments:

  • None.

FAQs
Denice S. Feig, MD, MSc, FRCPC has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Lorraine Lipscombe, MD, FRCPC has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Sonal Singh, MD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.